Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SRTM vs BDRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BDRX Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 6–2 Matrix Metrics)

BDRX Overall Winner 6-Pillar Tally: SRTM 1 – 3 BDRX (2 Tie) Matrix Metrics: SRTM 2 – 6 BDRX

As of Nov 20, 2026, Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) is the stronger overall head-to-head candidate over SRTM (SRTM) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SRTM carries a Unified Composite Score of 47.6/100 (HOLD) at $0.08 (N/M Forward P/E, N/A operating margin), whereas BDRX carries 36.0/100 (SELL) at $1.88 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While SRTM currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. BDRX 36.0/100 SELL), BDRX captures the overall institutional head-to-head verdict (6–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (-64.1% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRTM vs BDRX
SRTM US Equity
SRTM
Institutional Equity
$0.08
-14.59% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
47.6 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
BDRX NASDAQ Head-to-Head Winner
Biodexa Pharmaceuticals plc American Depositary Shs
Pharmaceutical Preparations
$1.88
-6.02% 1D
Market Cap $1.0M
TTM Revenue $83,000
Forward P/E N/M
Beta / 30D Vol 5.62β · 2621% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 15.0 Fund 36.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.6 · SMA20: $2.73 · SMA50: $1.46

6-Pillar Scorecard Institutional Category Breakdown (SRTM 1 – 3 BDRX)

Columns: Metric · SRTM · BDRX
1. Valuation Multiples BDRX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 12.6x
2. Growth & Scale BDRX
Revenue Growth (YoY) N/A -64.1%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $83,000
Market Cap N/A $1.0M
3. Profitability & Quality BDRX
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -42.0%
4. Balance Sheet & Cash Flow SRTM
Cash Generation (TTM) N/A -$8.8M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $138.06 Book/Sh · -42.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRTM (2) vs BDRX (6)
Institutional Metric SRTM BDRX Criterion Row Edge
Market Capitalization
Scale
N/A $1.0M Larger Scale BDRX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -64.1% Higher Growth BDRX
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin BDRX
Net Profit Margin
Profitability
N/A 0.0% Higher Margin BDRX
Return on Equity (ROE)
Capital Efficiency
N/A -42.0% Higher ROE BDRX
52-Week Range Position
Momentum
2% ($0–$1) 18% ($0–$9) Stronger Trend BDRX
Beta / 30D Volatility
Risk Regime
N/A 5.62β · 2621% Vol Lower Realized Risk SRTM
Unified Institutional Score
Composite Signal
47.6 / 100 (HOLD) 36.0 / 100 (SELL) Higher Composite SRTM
Trailing 12M Revenue (USD)
Operating Scale
N/A $83,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 12.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$8.8M EBITDA ($138.06 Book/Sh · -42.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BDRX +433.3 pp
SRTM: -80.4% · BDRX: +352.9%
3M Horizon BDRX +466.86 pp
SRTM: -86.83% · BDRX: +380.03%
6M Horizon BDRX +466.86 pp
SRTM: -86.83% · BDRX: +380.03%
1Y Horizon BDRX +466.86 pp
SRTM: -86.83% · BDRX: +380.03%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SRTM vs BDRX. Trailing 12-month operating profitability (SRTM N/A vs BDRX 0.0%) and valuation multiples (SRTM N/M vs BDRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SRTM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
BDRX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$83,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-42.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRTM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SRTM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BDRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BDRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRTM Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BDRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRTM vs BDRX Key Questions & Quantitative Answers

As of Nov 20, 2026, Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) is the stronger overall head-to-head candidate over SRTM (SRTM) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SRTM carries a Unified Composite Score of 47.6/100 (HOLD) at $0.08 (N/M Forward P/E, N/A operating margin), whereas BDRX carries 36.0/100 (SELL) at $1.88 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While SRTM currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. BDRX 36.0/100 SELL), BDRX captures the overall institutional head-to-head verdict (6–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (-64.1% vs. N/A YoY).

BDRX leads the Growth & Scale pillar: SRTM posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BDRX at -64.1% YoY revenue growth and +0.0% YoY earnings growth on $83,000 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SRTM generates N/A in USD-normalized revenue versus $83,000 for BDRX. In operating R&D and SG&A reinvestment, SRTM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BDRX.

BDRX screens cheaper on headline valuation multiples. SRTM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BDRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 12.6x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRTM (N/A ROE) versus BDRX (-42.0% ROE) capital efficiency.

In options market volatility and institutional positioning, SRTM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, BDRX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (5.62β · 2621% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.